We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


The Lipid Management Team Reflects on the ESC Congress; the World’s Largest Gathering of Cardiovascular Health Experts

The Lipid Management Team traveled to Barcelona last month to attend the European Society of Cardiology (ESC) Congress, the world’s… more

Posted by mlowe@esperion.com

Important Bempedoic Acid-Based Franchise Progress Updates

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our… more

Posted by mlowe@esperion.com

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Evolution of Cholesterol Lowering Treatments

In Part I of our “History of LDL-cholesterol” blog series, I sat down with cardiovascular and lipids specialist, Dr. Antonio… more

Posted by mlowe@esperion.com